“`html
AbbVie Inc. (ABBV) reported a significant 53% year-over-year surge in combined sales of its immunology drugs, Skyrizi and Rinvoq, totaling $18.5 billion as of 2023.
Skyrizi and Rinvoq now control about 50% of the Crohn’s disease market and nearly 33% of the ulcerative colitis market in the U.S. AbbVie forecasts that combined sales could exceed $25 billion by 2025 and surpass $31 billion by 2027, boosted by new indications and market share gains.
AbbVie continues to expand in oncology and neuroscience, with recent additions including Epkinly, Elahere, and Emrelis, as well as growth from migraine medications like Ubrelvy and Qulipta.
“`
